Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

IFN- alpha blocks IL-17 production by peripheral blood mononuclear cells in patients with chronic active hepatitis B Infection

Authors: Fang Cui, Jiangping Meng, Peng Luo, Pu Chen

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

IFN-α has been used to treat patients with chronic active hepatitis B (CAHB). Recent studies have implicated the IL-23/Th-17 pathway in the pathogenesis of CAHB. In this study, we investigated whether IFN-α could affect this pathway.

Methods

Peripheral blood mononuclear cells (PBMCs) obtained from patients with active CAHB (n = 61) and controls (n = 32) were cultured with or without IFN-α, and the levels of IL-17 and IL-10 in the supernatants were determined by ELISA, while the frequency of IL-17-expressing cells was measured by FACS. Similar experiments were also conducted with isolated CD4+ T cells from controls. Furthermore, an experiment using an anti-IL-10 antibody was performed to examine the underlying mechanisms of action of IFN-α.

Results

Both the levels of IL-17 and the frequency of IL-17-expressing cells were significantly higher in the PBMCs from CAHB patients than in the controls. IFN-α significantly decreased IL-17 production and the frequency of IL-17-expressing cells in PBMCs from both patients and controls. On the other hand, IFN-α increased IL-10 production by PBMCs from patients and controls. Anti-IL-10 antibody was able to neutralize the inhibitory effect of IFN-α on IL-17 production by PBMCs.

Conclusions

In vitro experiments showed that IFN-α could inhibit IL-17 expression and increase IL-10 production by PBMCs and CD4+ T cells. The inhibitory role of IFN-α on IL-17 production was partly mediated by IL-10.
Appendix
Available only for authorised users
Literature
1.
go back to reference Calvaruso V, Craxi A: Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol. 2011, 25: 219-230. 10.1016/j.bpg.2011.02.012.CrossRefPubMed Calvaruso V, Craxi A: Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol. 2011, 25: 219-230. 10.1016/j.bpg.2011.02.012.CrossRefPubMed
3.
go back to reference Zhang JY, Zhang Z, Lin F, et al: Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 2010, 51: 81-91. 10.1002/hep.23273.CrossRefPubMed Zhang JY, Zhang Z, Lin F, et al: Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 2010, 51: 81-91. 10.1002/hep.23273.CrossRefPubMed
4.
go back to reference Ye Y, Xie X, Yu J, et al: Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol. 2010, 30: 546-555. 10.1007/s10875-010-9416-3.CrossRefPubMed Ye Y, Xie X, Yu J, et al: Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol. 2010, 30: 546-555. 10.1007/s10875-010-9416-3.CrossRefPubMed
5.
go back to reference Hirohata S, Shibuya H, Tejima S: Suppressive influences of IFN-αlpha on IL-17 expression in human CD4+ T cells. Clin Immunol. 2010, 134: 340-344. 10.1016/j.clim.2009.11.012.CrossRefPubMed Hirohata S, Shibuya H, Tejima S: Suppressive influences of IFN-αlpha on IL-17 expression in human CD4+ T cells. Clin Immunol. 2010, 134: 340-344. 10.1016/j.clim.2009.11.012.CrossRefPubMed
6.
go back to reference Aman MJ, Tretter T, Eisenbeis I, et al: Interferon-alpha stimulates production of interleukin-10 in activated CD4 + T cells and monocytes. Blood. 1996, 87: 4731-4736.PubMed Aman MJ, Tretter T, Eisenbeis I, et al: Interferon-alpha stimulates production of interleukin-10 in activated CD4 + T cells and monocytes. Blood. 1996, 87: 4731-4736.PubMed
7.
go back to reference de Waal MR, Haanen J, Spits H, et al: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991, 174: 915-924. 10.1084/jem.174.4.915.CrossRef de Waal MR, Haanen J, Spits H, et al: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991, 174: 915-924. 10.1084/jem.174.4.915.CrossRef
8.
go back to reference Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD: IL-10 inhibits tumor antigen presentation by epidermalantigen-presenting cells. J Immunol. 1995, 154: 1280-1286.PubMed Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD: IL-10 inhibits tumor antigen presentation by epidermalantigen-presenting cells. J Immunol. 1995, 154: 1280-1286.PubMed
9.
go back to reference Fitzgerald DC, Zhang GX, El-Behi M, et al: Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol. 2007, 8: 1372-1379. 10.1038/ni1540.CrossRefPubMed Fitzgerald DC, Zhang GX, El-Behi M, et al: Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol. 2007, 8: 1372-1379. 10.1038/ni1540.CrossRefPubMed
10.
go back to reference European Association for the Study of the Liver: EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009, 50: 227-242.CrossRef European Association for the Study of the Liver: EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009, 50: 227-242.CrossRef
11.
go back to reference Asian-Pacific consensus statement on the management of chronic hepatitisB: a 2012 update. Hepatol Int. 2012, 6: 531-56. 10.1007/s12072-012-9365-4. Asian-Pacific consensus statement on the management of chronic hepatitisB: a 2012 update. Hepatol Int. 2012, 6: 531-56. 10.1007/s12072-012-9365-4.
12.
go back to reference Zhao L, Tang Y, You Z, et al: Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011, 6: e18909-10.1371/journal.pone.0018909.CrossRefPubMedPubMedCentral Zhao L, Tang Y, You Z, et al: Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011, 6: e18909-10.1371/journal.pone.0018909.CrossRefPubMedPubMedCentral
13.
go back to reference Ge J, Wang K, Meng QH, et al: Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol. 2010, 30: 60-67. 10.1007/s10875-009-9328-2.CrossRefPubMed Ge J, Wang K, Meng QH, et al: Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol. 2010, 30: 60-67. 10.1007/s10875-009-9328-2.CrossRefPubMed
14.
go back to reference Wu W, Li J, Chen F, et al: Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients. J Gastroenterol Hepatol. 2010, 25: 750-757. 10.1111/j.1440-1746.2009.06154.x.CrossRefPubMed Wu W, Li J, Chen F, et al: Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients. J Gastroenterol Hepatol. 2010, 25: 750-757. 10.1111/j.1440-1746.2009.06154.x.CrossRefPubMed
15.
go back to reference Li J, Wu W, Peng G, et al: HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients. Immunol Cell Biol. 2010, 88: 834-841. 10.1038/icb.2010.63.CrossRefPubMed Li J, Wu W, Peng G, et al: HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients. Immunol Cell Biol. 2010, 88: 834-841. 10.1038/icb.2010.63.CrossRefPubMed
16.
go back to reference Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 Cells. Annu Rev Immunol. 2009, 27: 485-517. 10.1146/annurev.immunol.021908.132710.CrossRefPubMed Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 Cells. Annu Rev Immunol. 2009, 27: 485-517. 10.1146/annurev.immunol.021908.132710.CrossRefPubMed
17.
go back to reference Meyer O, et al: Interferons and autoimmune disorders. Joint Bone Spine. 2009, 76: 464-473. 10.1016/j.jbspin.2009.03.012.CrossRefPubMed Meyer O, et al: Interferons and autoimmune disorders. Joint Bone Spine. 2009, 76: 464-473. 10.1016/j.jbspin.2009.03.012.CrossRefPubMed
18.
go back to reference Finter NB, Chapman S, Dowd P, et al: The use of interferon-alpha in virus infections. Drugs. 1991, 42: 749-765. 10.2165/00003495-199142050-00003.CrossRefPubMed Finter NB, Chapman S, Dowd P, et al: The use of interferon-alpha in virus infections. Drugs. 1991, 42: 749-765. 10.2165/00003495-199142050-00003.CrossRefPubMed
19.
go back to reference Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S: IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol. 2009, 182: 3928-3936. 10.4049/jimmunol.0802226.CrossRefPubMed Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S: IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol. 2009, 182: 3928-3936. 10.4049/jimmunol.0802226.CrossRefPubMed
20.
go back to reference Penton-Rol G, Cervantes-Llanos M, Cabrera-Gomez JA, et al: Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells frommultiple sclerosis patients. Int Immunopharmacol. 2008, 8: 881-886. 10.1016/j.intimp.2008.02.003.CrossRefPubMed Penton-Rol G, Cervantes-Llanos M, Cabrera-Gomez JA, et al: Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells frommultiple sclerosis patients. Int Immunopharmacol. 2008, 8: 881-886. 10.1016/j.intimp.2008.02.003.CrossRefPubMed
21.
go back to reference Kubota N, Ebihara T, Matsumoto M, et al: IL-6 and IFN-αlpha from dsRNA-stimulated dendritic cells control expansion of regulatory T cells. Biochem Biophys Res Commun. 2010, 391: 1421-1426. 10.1016/j.bbrc.2009.12.081.CrossRefPubMed Kubota N, Ebihara T, Matsumoto M, et al: IL-6 and IFN-αlpha from dsRNA-stimulated dendritic cells control expansion of regulatory T cells. Biochem Biophys Res Commun. 2010, 391: 1421-1426. 10.1016/j.bbrc.2009.12.081.CrossRefPubMed
22.
go back to reference Pirhonen J, Siren J, Julkunen I, Matikainen S: IFN-αlpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J Leukoc Biol. 2007, 82: 1185-1192. 10.1189/jlb.0307157.CrossRefPubMed Pirhonen J, Siren J, Julkunen I, Matikainen S: IFN-αlpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J Leukoc Biol. 2007, 82: 1185-1192. 10.1189/jlb.0307157.CrossRefPubMed
23.
go back to reference Diveu C, McGeachy MJ, Boniface K, et al: IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol. 2009, 182: 5748-5756. 10.4049/jimmunol.0801162.CrossRefPubMed Diveu C, McGeachy MJ, Boniface K, et al: IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol. 2009, 182: 5748-5756. 10.4049/jimmunol.0801162.CrossRefPubMed
Metadata
Title
IFN- alpha blocks IL-17 production by peripheral blood mononuclear cells in patients with chronic active hepatitis B Infection
Authors
Fang Cui
Jiangping Meng
Peng Luo
Pu Chen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-55

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.